132 related articles for article (PubMed ID: 37857483)
1. Gene of the month: cancer testis antigen gene 1b (NY-ESO-1).
Julve M; Kennedy O; Frampton AE; Bagwan I; Lythgoe MP
J Clin Pathol; 2023 Dec; 77(1):1-7. PubMed ID: 37857483
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
3. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
Gjerstorff MF; Pøhl M; Olsen KE; Ditzel HJ
BMC Cancer; 2013 Oct; 13():466. PubMed ID: 24103781
[TBL] [Abstract][Full Text] [Related]
4. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.
Pollack SM; Li Y; Blaisdell MJ; Farrar EA; Chou J; Hoch BL; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
PLoS One; 2012; 7(2):e32165. PubMed ID: 22384167
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis.
Smith SM; Iwenofu OH
Chin Clin Oncol; 2018 Aug; 7(4):44. PubMed ID: 30173534
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
7. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Raza A; Merhi M; Inchakalody VP; Krishnankutty R; Relecom A; Uddin S; Dermime S
J Transl Med; 2020 Mar; 18(1):140. PubMed ID: 32220256
[TBL] [Abstract][Full Text] [Related]
8. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
9. Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
Park TS; Groh EM; Patel K; Kerkar SP; Lee CC; Rosenberg SA
J Immunother; 2016 Jan; 39(1):1-7. PubMed ID: 26641256
[TBL] [Abstract][Full Text] [Related]
10. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
11. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H
BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
14. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
[TBL] [Abstract][Full Text] [Related]
15. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
Endo M; de Graaff MA; Ingram DR; Lim S; Lev DC; Briaire-de Bruijn IH; Somaiah N; Bovée JV; Lazar AJ; Nielsen TO
Mod Pathol; 2015 Apr; 28(4):587-95. PubMed ID: 25412843
[TBL] [Abstract][Full Text] [Related]
17. Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.
Gupta R; Jit BP; Kumar S; Mittan S; Tanwer P; Ray MD; Mathur S; Perumal V; Kumar L; Rath GK; Sharma A
Epigenomics; 2022 Jul; 14(14):865-886. PubMed ID: 35872653
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
19. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
